Tran Van L, Greenberg Joy, Nuibe Andrew
J Pediatr Pharmacol Ther. 2021;26(7):728-733. doi: 10.5863/1551-6776-26.7.728. Epub 2021 Sep 24.
With no consensus, the practice of using prophylactic antibiotics prior to central venous catheter (CVC) removal in NICU patients remains controversial. The objective of this study was to compare the incidence of sepsis post-CVC removal in those who received a dose of vancomycin prophylactically with those who did not.
This single-center, retrospective chart review included NICU patients who had CVCs removed. Patients were excluded if they had a confirmed or suspected infection at the time of CVC removal or if the indwelling CVC was removed prior to 30 days from insertion. Primary outcome was the occurrence of a sepsis evaluation within 72 hours from CVC removal. Secondary outcomes included the development of acute kidney injury, source and identification of positive cultures, time to onset of suspected or confirmed sepsis, and the appropriate administration of intravenous vancomycin.
Eighty-two CVC removals received prophylactic vancomycin (P-VAN), and 22 CVCs did not receive prophylactic vancomycin (NP-VAN) prior to CVC removal. There were no significant differences in patient demographics between groups and median duration of indwelling CVC. Two clinical sepsis evaluations occurred in the P-VAN group compared with none in the NP-VAN group. Of all the P-VAN CVC removals, 45 (55%) received vancomycin appropriately. There were no statistical differences in all evaluated secondary outcomes.
Vancomycin administered prophylactically prior to CVC removal did not reduce the number of subsequent clinical sepsis evaluations or infections in NICU patients.
由于尚无共识,在新生儿重症监护病房(NICU)患者拔除中心静脉导管(CVC)前使用预防性抗生素的做法仍存在争议。本研究的目的是比较接受一剂万古霉素预防性治疗的患者与未接受预防性治疗的患者在拔除CVC后发生败血症的发生率。
这项单中心回顾性病历审查纳入了拔除CVC的NICU患者。如果患者在拔除CVC时已确诊或疑似感染,或者留置的CVC在插入后30天内拔除,则将其排除。主要结局是拔除CVC后72小时内进行败血症评估的情况。次要结局包括急性肾损伤的发生、阳性培养物的来源和鉴定、疑似或确诊败血症的发病时间,以及静脉注射万古霉素的合理使用情况。
82例CVC拔除术前接受了预防性万古霉素治疗(P-VAN组),22例CVC拔除术前未接受预防性万古霉素治疗(NP-VAN组)。两组患者的人口统计学特征和CVC留置的中位时间无显著差异。P-VAN组发生了2次临床败血症评估,而NP-VAN组未发生。在所有接受P-VAN治疗的CVC拔除术中,45例(55%)万古霉素使用合理。所有评估的次要结局均无统计学差异。
在拔除CVC前预防性使用万古霉素并不能减少NICU患者随后的临床败血症评估次数或感染发生率。